pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
LaFleur Minerals Closes LIFE, Flow Thru and Final Hard Dollar Offering for $900,000 to Complete Total of $7,800,421 Funding to Restart Beacon Gold Mill Production Operations in Abitibi Greenstone Belt
Nextech3D.ai Closes Krafty Labs Acquisition Expanding into a Comprehensive End-to-End AI-Powered Live Events and Experiential Engagement Platform
